MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast on Monday, November 2, 2009 to provide an update regarding the New Drug Application for toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy.
